Drug Development

US FDA Approves Extavia® - The First In A New Portfolio Of Planned MS Therapies From Novartis To Help Patients With This

Source -- http://insciences.org/article.php?article_id=6494

. Extavia is branded version of interferon beta-1b, a standard-of-care for multiple sclerosis in the US for more than 16 years[1]
. MS affects around 400,000 people in US[2] - one of the most common neurological disorders in young adults[3]
. FDA approval marks important step forward for Novartis, laying foundation for innovative approach to treatment of MS


An Anti-Anxiety Drug That Could Create Super-Soldiers

Molecule

By Annalee Newitz

Soon you may be able to buy a drug that can make you calm by mimicking the body's natural self-soothing process. But you wouldn't feel drugged. What would happen to people who suddenly became fearless without side-effects?


Model Based Drug Development

01/12/2009 - 08:00
01/13/2009 - 17:15

Host: ExL Pharma
Time: 8:00 AM - 5:15 PM
Location: Loews Philadelphia Hotel
Contact: Sarah Ide
Phone: 212-400-6240
Toll Free Phone: NA
Fax: 888-221-6750
Email: info@exlpharma.com
Website: http://www.exlpharma.com/eventDetail.php?id=148


Syndicate content